Efficacy and Safety of Grass Pollen Sublingual Immunotherapy

NCT00567346 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

605

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Rhinoconjunctivitis

Interventions

DRUG: Oralgen
DRUG: grass pollen extract

Sponsor

Artu Biologicals